Irene M Stratton

List of Publications by Year
in descending order

140 papers	25,274 citations	44042 48 h-index	14197 128 g-index
143 all docs	143 docs citations	143 times ranked	18823 citing authors

#	Article	IF	Citations
1	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ: British Medical Journal, 2000, 321, 405-412.	2.4	7,060
2	International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet, The, 2002, 360, 1267-1274.	6.3	3,333
3	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ: British Medical Journal, 2000, 321, 412-419.	2.4	1,737
4	Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ: British Medical Journal, 1998, 316, 823-828.	2.4	1,706
5	UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia, 2001, 44, 156-163.	2.9	840
6	The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clinical Science, 2001, 101, 671-679.	1.8	734
7	UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet, The, 1997, 350, 1288-1293.	6.3	704
8	The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clinical Science, 2001, 101, 671.	1.8	695
9	A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 2004, 47, 1747-1759.	2.9	516
10	United Kingdom Prospective Diabetes Study, 30. JAMA Ophthalmology, 1998, 116, 297.	2.6	410
11	UKPDS 60. Stroke, 2002, 33, 1776-1781.	1.0	391
12	Risks of Progression of Retinopathy and Vision Loss Related to TightBlood Pressure Control in Type 2 Diabetes Mellitus. JAMA Ophthalmology, 2004, 122, 1631.	2.6	377
13	The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clinical Science, 2001, 101, 671-9.	1.8	371
14	UKPDS 59: Hyperglycemia and Other Potentially Modifiable Risk Factors for Peripheral Vascular Disease in Type 2 Diabetes. Diabetes Care, 2002, 25, 894-899.	4.3	349
15	Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia, 2006, 49, 1761-1769.	2.9	303
16	UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. , 1998, 15, 297-303.		290
17	Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care, 1999, 22, 495-502.	4.3	273
18	Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ: British Medical Journal, 2000, 320, 1373-1378.	2.4	269

#	Article	IF	Citations
19	Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology, 1999, 50, 561-567.	1.2	255
20	Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes: UKPDS 66. Diabetes Care, 2004, 27, 201-207.	4.3	254
21	How to deal with regression to the mean in intervention studies. Lancet, The, 1996, 347, 241-243.	6.3	186
22	Risk Factors for Stroke in Type 2 Diabetes Mellitus. Archives of Internal Medicine, 1999, 159, 1097.	4.3	173
23	Group Sequential Clinical Trials with Triangular Continuation Regions. Biometrics, 1983, 39, 227.	0.8	164
24	Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clinical Endocrinology, 1999, 51, 281-284.	1.2	163
25	Comparison of 11 Human Insulin Assays: Implications for Clinical Investigation and Research. Clinical Chemistry, 2007, 53, 922-932.	1.5	145
26	Microaneurysms in the development of diabetic retinopathy (UKPDS 42). Diabetologia, 1999, 42, 1107-1112.	2.9	124
27	Cancer near nuclear installations. Nature, 1987, 329, 499-505.	13.7	118
28	Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). Diabetologia, 1999, 42, 608-616.	2.9	116
29	High Prevalence of Hepatitis C Infection in Afroâ€Caribbean Patients with Type 2 Diabetes and Abnormal Liver Function Tests. Diabetic Medicine, 1995, 12, 244-249.	1.2	114
30	A method for assessing quality of control from glucose profiles. Diabetic Medicine, 2007, 24, 753-758.	1.2	108
31	UKPDS 19: Heterogeneity in NIDDM: separate contributions of IRS-1 and b3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. Diabetologia, 1996, 39, 1505-1511.	2.9	101
32	Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia, 2005, 48, 695-702.	2.9	101
33	Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabetic Medicine, 2001, 18, 178-184.	1.2	99
34	Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ: British Medical Journal, 1995, 310, 569-573.	2.4	97
35	Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51). Diabetologia, 2001, 44, 298-304.	2.9	90
36	Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technology Assessment, 2015, 19, 1-116.	1.3	90

#	Article	IF	Citations
37	Prospective evaluation of an artificial intelligence-enabled algorithm for automated diabetic retinopathy screening of 30Â000 patients. British Journal of Ophthalmology, 2021, 105, 723-728.	2.1	89
38	Incidence of AIDS and excess of mortality associated with HIV in haemophiliacs in the United Kingdom: report on behalf of the directors of haemophilia centres in the United Kingdom.. BMJ: British Medical Journal, 1989, 298, 1064-1068.	2.4	85
39	Cohort profile: design and methods in the eye and vision consortium of UK Biobank. BMJ Open, 2019, 9, e025077.	0.8	85
40	Epidemiological issues in diabetic retinopathy. Middle East African Journal of Ophthalmology, 2013, 20, 293.	0.5	80
41	U.K. Prospective Diabetes Study XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM. Kidney International, 1995, 48, 1907-1911.	2.6	77
42	U.K. Prospective Diabetes Study 22: Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care, 1997, 20, 1435-1441.	4.3	76
43	Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia, 2009, 52, 50-59.	2.9	70
44	Lack of confidence among trainee doctors in the management of diabetes: the Trainees Own Perception of Delivery of Care (TOPDOC) Diabetes Study. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 761-766.	0.2	69
45	A Simple Risk Stratification for Time to Development of Sight-Threatening Diabetic Retinopathy. Diabetes Care, 2013, 36, 580-585.	4.3	66
46	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 363-369.	1.5	64
47	Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). Diabetic Medicine, 2000, 17, 518-523.	1.2	63
48	United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye, 2013, 27, 1397-1404.	1.1	56
49	Attitudes, access and anguish: a qualitative interview study of staff and patientsâ€™ experiences of diabetic retinopathy screening. BMJ Open, 2014, 4, e005498.	0.8	55
50	The influence of method of contraception and cigarette smoking on menstrual patterns. BJOG: an International Journal of Obstetrics and Gynaecology, 1988, 95, 905-910.	1.1	48
51	Influence of primary care practices on patientsâ€™ uptake of diabetic retinopathy screening: a qualitative case study. British Journal of General Practice, 2014, 64, e484-e492.	0.7	47
52	Screening attendance, age group and diabetic retinopathy level at first screen. Diabetic Medicine, 2016, 33, 904-911.	1.2	46
53	Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women. Journal of the American Heart Association, 2015, 4, e002258.	1.6	44
54	UK Prospective Diabetes Study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM. Diabetologia, 1995, 38, 948-952.	2.9	42

#	Article	IF	Citations
55	Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals. Diabetes Care, 2015, 38, 488-494.	4.3	41
56	Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?. Eye, 2013, 27, 56-64.	1.1	40
57	Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabetic Medicine, 2005, 22, 306-311.	1.2	38
58	UKPDS 18: Estimated Dietary Intake in Type 2 Diabetic Patients Randomly Allocated to Diet, Sulphonylurea or Insulin Therapy. Diabetic Medicine, 1996, 13, 656-662.	1.2	35
59	Validation of an algorithm combining haemoglobin A_{1c} and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations. Diabetic Medicine, 2009, 26, 115-121.	1.2	35
60	Delay in diabetic retinopathy screening increases the rate of detection of referable diabetic retinopathy. Diabetic Medicine, 2014, 31, 439-442.	1.2	33
61	Preanalytical, Analytical, and Computational Factors Affect Homeostasis Model Assessment Estimates. Diabetes Care, 2008, 31, 1877-1883.	4.3	31
62	Factors determining uptake of diabetic retinopathy screening in Oxfordshire. Diabetic Medicine, 2017, 34, 993-999.	1.2	31
63	Approach to maintaining comparability of biochemical data during long-term clinical trials. Clinical Chemistry, 1997, 43, 1913-1918.	1.5	30
64	Glycaemic control and familial factors determine hyperlipidaemia in early childhood diabetes. Diabetic Medicine, 1999, 16, 598-604.	1.2	29
65	Individualised variable-interval risk-based screening for sight-threatening diabetic retinopathy: the Liverpool Risk Calculation Engine. Diabetologia, 2017, 60, 2174-2182.	2.9	29
66	Associations with Corneal Hysteresis in a Population Cohort. Ophthalmology, 2019, 126, 1500-1510.	2.5	29
67	Repeated Significance Tests for Clinical Trials with a Fixed Number of Patients and Variable Follow-Up. Biometrics, 1985, 41, 353.	0.8	28
68	Rapid and simultaneous detection of multiple mutations by pooled and multiplex single nucleotide primer extension: application to the study of insulin-responsive glucose transporter and insulin receptor mutations in non-insulindependent diabetes. Human Molecular Genetics, 1992, 1, 391-395.	1.4	28
69	Quantile regression analysis reveals widespread evidence for gene-environment or gene-gene interactions in myopia development. Communications Biology, 2019, 2, 167.	2.0	27
70	Insights From Survival Analyses During 12 Years of Antiâ€“Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2021, 139, 57.	1.4	27
71	Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia. Diabetologia, 2009, 52, 172-174.	2.9	26
72	System-level and patient-level explanations for non-attendance at diabetic retinopathy screening in Sutton and Merton (London, UK): a qualitative analysis of a service evaluation: TableÂ1. BMJ Open, 2016, 6, e010952.	0.8	26

#	Article	IF	Citations
73	The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. Acta Ophthalmologica, 2013, 91, e335-9.	0.6	25
74	Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy. Eye, 2019, 33, 640-647.	1.1	25
75	Mortality of nitrate fertiliser workers.. Occupational and Environmental Medicine, 1986, 43, 507-515.	1.3	24
76	Analysis of the Hexokinase II Gene in Subjects With Insulin Resistance and NIDDM and Detection of a Gln142â†'His Substitution. Diabetes, 1995, 44, 340-346.	0.3	23
77	Risk of diabetic retinopathy at first screen in children at 12 and 13 years of age. Diabetic Medicine, 2016, 33, 1655-1658.	1.2	23
78	Trends in diabetic retinopathy screening attendance and associations with vision impairment attributable to diabetes in a large nationwide cohort. Diabetic Medicine, 2021, 38, e14425.	1.2	23
79	Chromosome 4q locus associated with insulin resistance in Pima Indians. Studies in three European NIDDM populations. Diabetes, 1994, 43, 800-804.	0.3	23
80	Multi-trait genome-wide association study identifies new loci associated with optic disc parameters. Communications Biology, 2019, 2, 435.	2.0	22
81	Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT. Diabetologia, 2021, 64, 56-69.	2.9	22
82	Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control. Diabetologia, 1996, 39, 1554-1561.	2.9	21
83	Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478). Journal of Diabetes Science and Technology, 2019, 13, 498-506.	1.3	20
84	Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. Eye, 2015, 29, 403-408.	1.1	19
85	An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). Diabetic Medicine, 2001, 18, 438-444.	1.2	18
86	Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes. Diabetes Research and Clinical Practice, 2003, 60, 105-110.	1.1	18
87	Individualised screening for diabetic retinopathy: the ISDR studyâ€"rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening. BMJ Open, 2019, 9, e025788.	0.8	18
88	Geographical variation in certification rates of blindness and sight impairment in England, 2008â€"2009. BMJ Open, 2012, 2, e001496.	0.8	17
89	Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 2639-2645.	1.0	17
90	The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. Eye, 2016, 30, 1462-1468.	1.1	16

#	Article	IF	Citations
91	Personalized riskâ€based screening for diabetic retinopathy: A multivariate approach versus the use of stratification rules. Diabetes, Obesity and Metabolism, 2019, 21, 560-568.	2.2	16
92	Rate of change (modulation) of serum growth hormone concentrations is a more important factor in determining growth rate than duration of exposure. Clinical Endocrinology, 1992, 36, 165-170.	1.2	15
93	Associations with photoreceptor thickness measures in the UK Biobank. Scientific Reports, 2019, 9, 19440.	1.6	15
94	A prospective study of urinary androgen levels and ovarian cancer. International Journal of Cancer, 1983, 32, 723-726.	2.3	14
95	Agreement and reasons for disagreement between photographic and hospital biomicroscopy grading of diabetic retinopathy. Diabetic Medicine, 2011, 28, 741-746.	1.2	13
96	The use of statistical methodology to determine the accuracy of grading within a diabetic retinopathy screening programme. Diabetic Medicine, 2016, 33, 896-903.	1.2	13
97	Increasing use of private practice by patients in Oxford requiring common elective surgical operations.. BMJ: British Medical Journal, 1985, 291, 797-799.	2.4	12
98	Development and validation of a Diabetes Risk Score for screening undiagnosed diabetes in Sri Lanka (SLDRISK). BMC Endocrine Disorders, 2016, 16, 42.	0.9	12
99	Renoprotective effects of renin-angiotensin-system inhibitors. Lancet, The, 2006, 367, 897-898.	6.3	11
100	Comparison of IFCC-calibrated HbA1c from laboratory and point of care testing systems. Diabetes Research and Clinical Practice, 2014, 105, 364-372.	1.1	11
101	UKPDS58â€"modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes. Journal of Diabetes and Its Complications, 2002, 16, 371-376.	1.2	10
102	Utility of HbA_{1c} assessment in people with diabetes awaiting liver transplantation. Diabetic Medicine, 2019, 36, 1444-1452.	1.2	10
103	Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire. Acta Ophthalmologica, 2022, 100, .	0.6	10
104	The physiological action of gliclazide: Î²-cell function and insulin resistance. Diabetes Research and Clinical Practice, 1991, 14, S53-S59.	1.1	9
105	Microsatellite Polymorphisms at the Glucokinase Locus: a Population Association Study in Caucasian Type 2 Diabetic Subjects. Diabetic Medicine, 1993, 10, 694-698.	1.2	8
106	A Potential Pathway for Managing Diabetic Patients with Arterial Emboli Detected by Retinal Screening. European Journal of Vascular and Endovascular Surgery, 2011, 42, 153-157.	0.8	8
107	Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years. Eye, 2022, 36, 72-77.	1.1	8
108	Approach to maintaining comparability of biochemical data during long-term clinical trials. Clinical Chemistry, 1997, 43, 1913-8.	1.5	8

#	Article	IF	Citations
109	The use of weighted healthâ€related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial. Diabetic Medicine, 2015, 32, 97-101.	1.2	7
110	Prevalence and pathophysiology of impaired glucose tolerance in three different high-risk white groups. Metabolism: Clinical and Experimental, 1993, 42, 932-938.	1.5	6
111	Can HbA1c detect undiagnosed diabetes in acute medical hospital admissions?. Diabetes Research and Clinical Practice, 2016, 115, 106-114.	1.1	6
112	Prevalence of admission plasma glucose in 'diabetes'Âor 'at risk' ranges in hospital emergencies with no prior diagnosis of diabetes by gender, age and ethnicity. Endocrinology, Diabetes and Metabolism, 2020, 3, e00140.	1.0	6
113	Of insulin resistance and normalcy. Diabetologia, 1992, 35, 696-698.	2.9	5
114	The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clinical Science, 2002, 102, 679-679.	1.8	5
115	Agreement between Photographic Screening and Hospital Biomicroscopy Grading of Diabetic Retinopathy and Maculopathy. European Journal of Ophthalmology, 2014, 24, 550-558.	0.7	5
116	Differences in level of confidence in diabetes care between different groups of trainees: the TOPDOC diabetes study. BMC Medical Education, 2014, 14, 191.	1.0	5
117	How to ensure your paper is rejected by the statistical reviewer. Diabetic Medicine, 2005, 22, 371-373.	1.2	4
118	Ophthalmic statistics note 13: method agreement studies in ophthalmologyâ€”please donâ€™t carry on correlatingâ€¦. British Journal of Ophthalmology, 2019, 103, 1201-1203.	2.1	4
119	Personalising screening of sight-threatening diabetic retinopathy - qualitative evidence to inform effective implementation. BMC Public Health, 2020, 20, 881.	1.2	4
120	Incidence of sightâ€threatening diabetic retinopathy in an established urban screening programme: An 11â€year cohort study. Diabetic Medicine, 2021, 38, e14583.	1.2	4
121	A simple algorithm to estimate the time to development of sight-threatening diabetic retinopathy. Lancet, The, 2012, 380, S69.	6.3	3
122	Risk stratification for diabetic eye screening. Diabetologia, 2014, 57, 259-259.	2.9	3
123	Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort. British Journal of Ophthalmology, 2021, , bjophthalmol-2020-318570.	2.1	3
124	Updating Diabetic Retinopathy Screening Lists using Automatic Extraction from GP Patient Records. Journal of Medical Screening, 2013, 20, 111-117.	1.1	2
125	Epidemiology of moderately severe and severe non-proliferative diabetic retinopathy in South West England. Eye, 2021, , .	1.1	2
126	Recommendations for designing tables that report randomized trials. Diabetic Medicine, 2007, 24, 1309-1312.	1.2	1

#	Article	IF	Citations
127	Diabetic CVI figures for England and Wales (2007â€“2009): Table 1. British Journal of Ophthalmology, 2012, 96, 1046.2-1047.	2.1	1
128	Data from UK Biobank on febrile illness. Eye, 2016, 30, 1650-1651.	1.1	1
129	Ophthalmic statistics note 14: method agreement studies in ophthalmology: the intraclass correlation coefficient?. British Journal of Ophthalmology, 2020, 104, 1033-1035.	2.1	1
130	1312-P: Admission Plasma Glucose and HbA1c in Emergency Hospital Admissions by Ethnicity. Diabetes, 2019, 68, .	0.3	1
131	Letter: Reply from T. Greenhalgh. , 1997, 14, 709-709.		0
132	Dietary advice? Authors' response and erratum for â€˜Effects of three monthsâ€™ diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)'. Diabetic Medicine, 2001, 18, 251-251.	1.2	0
133	Algorithm combining HbA_{1c} and fasting plasma glucose for screening subjects for OGTT: Authors' response. Diabetic Medicine, 2009, 26, 831-833.	1.2	0
134	Response to Comment on Leese et al. Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals. Diabetes Care 2015;38:488â€“494. Diabetes Care, 2015, 38, e209-e210.	4.3	0
135	The National Radium-223 Dichloride Audit Group: Data from Patients in 17 UK Oncology Centres with Metastatic Castrate-resistant Prostate Cancer Treated with Radium-223 Dichloride. Clinical Oncology, 2019, 31, e24.	0.6	0
136	The statistician will see you nowâ€¦. Diabetic Medicine, 2021, 38, e14437.	1.2	0
137	Dietary advice? Authors' response and erratum for 'Effects of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)'. Diabetic Medicine, 2001, 18, 251-251.	1.2	0
138	The National Radium-223 Dichloride Audit group: Data from patients in UK oncology centers with metastatic castration-resistant prostate cancer treated with radium-223 dichloride.. Journal of Clinical Oncology, 2019, 37, e16524-e16524.	0.8	0
139	39-LB: Individualised Screening for Diabetic Retinopathy: The ISDR Studyâ€”A Randomised Controlled Trial of Safety, Efficacy, and Cost-Effectiveness. Diabetes, 2019, 68, 39-LB.	0.3	0
140	Statistical Considerations in Diabetes Trials. , 0, , 387-393.		0